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Abstract
The G‐protein‐coupled receptor GPR132, also known as G2A, is activated by 9‐hydroxy‐
octadecadienoic	acid	(9‐HODE)	and	other	oxidized	fatty	acids.	Other	suggested	GPR132	
agonists	including	lysophosphatidylcholine	(LPC)	have	not	been	readily	reproduced.	Here,	
we identify N‐acylamides in particular N‐acylglycines, as lipid activators of GPR132 with 
comparable	activity	to	9‐HODE.	The	order‐of‐potency	is	N‐palmitoylglycine	>	9‐HODE	≈	
N‐linoleoylglycine	>	linoleamide	>	N‐oleoylglycine	≈	N‐stereoylglycine > N‐arachidonoyl‐
glycine > N‐docosehexanoylglycine. Physiological concentrations of N‐acylglycines in 
tissue are sufficient to activate GPR132. N‐linoleoylglycine	and	9‐HODE	also	activate	
rat and mouse GPR132, despite limited sequence conservation to human. We describe 
pharmacological tools for GPR132, identified through drug screening. SKF‐95667 is 
a novel GPR132 agonist. SB‐583831 and SB‐583355 are peptidomimetic molecules  
containing	core	amino	acids	(glycine	and	phenylalanine,	respectively),	and	structurally	
related to previously described ligands. A telmisartan analog, GSK1820795A, antago‐
nizes	the	actions	of	N‐acylamides at GPR132. The synthetic cannabinoid CP‐55 940 also 
activates GPR132. Molecular docking to a homology model suggested a site for lipid 
binding, predicting the acyl side‐chain to extend into the membrane bilayer between 
TM4 and TM5 of GPR132. Small‐molecule ligands are envisaged to occupy a “classical” 
site encapsulated in the 7TM bundle. Structure‐directed mutagenesis indicates a critical 
role for arginine at position 203 in transmembrane domain 5 to mediate GPR132 activa‐
tion by N‐acylamides.	Our	data	suggest	distinct	modes	of	binding	for	small‐molecule	and	
lipid agonists to the GPR132 receptor. Antagonists, such as those described here, will be 
vital to understand the physiological role of this long‐studied target.
K E Y W O R D S
G protein‐coupled receptor, G2A, GPR132, N‐acylglycine, N‐linoleoylglycine, N‐palmitoylglycine
Abbreviations:	9‐HODE,	9‐hydroxyoctadecadienoic	acid;	LPC,	lysophosphatidylcholine;	GPCRs,	G‐protein‐coupled	receptors;	AEA,	arachidonoyl	ethanolamide;	 
NAGly, N‐arachidonylglycine.
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1  | INTRODUC TION
N‐acylamides, also known as lipoamines, are a family of diverse nat‐
urally occurring lipids derived from the conjugation of saturated, un‐
saturated, or hydroxylated fatty acids to amines such as dopamine, 
ethanolamine, or amino acids (or simply to amide, as in linoleam‐
ide).	 Recent	 lipidomic	 studies	 confirm	 the	widespread	 occurrence	
of N‐acylamides in mammalian tissue, including brain.1 The family 
includes the endocannabinoid N‐arachidonoyl ethanolamide (AEA, 
also	known	as	anandamide),	and	the	cannabinoid	system	is	the	best	
understood signalling pathway in the class, with cognate G‐protein‐
coupled	receptors	 (GPCRs)	CB1 and CB2 and well‐elucidated path‐
ways for synthesis and degradation of AEA.2	Other	N‐acylamides 
have demonstrated biological effects, but generally the molecular 
targets or receptors mediating these effects are not yet clear.3
N‐acyl amino acids have received particular attention in recent 
years, with the demonstration that they occur in mammalian tissues 
at concentrations comparable to other lipid signalling mediators. 
Moreover several N‐acyl amino acids are biologically active (see 
Ref. 4	for	review).	A	human	biosynthetic	enzyme	for	N‐acylglycines, 
GLYATL2 (glycine N‐acyltransferase‐like 2, Ref.5),	and	N‐acyl amide 
synthase genes genes in gut bacteria6,7	further	emphasizes	their	im‐
portance. N‐arachidonylglycine	(NAGly),	the	first‐discovered	N‐acyl 
amino acid, is reported to activate the orphan GPCR, GPR188‐10 
and the lysophosphatidic acid receptor LPA5.
11 NAGly concentra‐
tions detected in brain are remarkably high and may exceed AEA.12 
Literature suggests NAGly may be involved in nociception, inflam‐
mation, and regulation of ocular pressure.4 Physiological processes 
for NAGly beyond GPCR signalling have also been proposed, includ‐
ing	modulation	 of	 transporters,	 ion	 channels,	 and	 enzymes,	 espe‐
cially	the	AEA‐degrading	enzyme,	fatty	acid	amide	hydrolase	(FAAH,	
Ref.4).
Here we show that N‐acylglycines activate another orphan fam‐
ily	A	GPCR,	namely	GPR132	(originally	called	G2A).	The	most	potent	
N‐acylglycine activators of GPR132 are N‐palmitoylglcine	 (NPGly)	
and N‐linoleoylglcine	(NLGly)	which	have	mono‐unsaturated	or	sat‐
urated acyl side‐chains. NAGly has weak agonist activity on GPR132 
and is unlikely to be a physiologically relevant ligand. NPGly and 
NLGly	bear	structural	similarity	to	the	oxidized	fatty	acid,	9‐HODE,	
the candidate endogenous GPR132 ligand.13‐15 Administered orally, 
NLGly reduces leukocyte migration in a mouse peritonitis model.16 
In	vivo	and	in	vitro,	NLGly	can	stimulate	production	of	prostaglandin	
15‐deoxy‐Δ12,14‐PGJ2, an inflammation‐resolving eicosanoid, from 
macrophages and macrophage‐like mouse RAW cells, respectively.16 
Biological activity of N‐acylglycines	 and	 oxidized	 fatty‐acids	 coin‐
cides with GPR132 location, in lymphocytes,17,18 monocyte‐lineage 
cells including macrophages19 and keratinocytes.20 GPR132 is im‐
plicated in diverse functions including nociception,21,22 positioning 
of macrophages at sites of inflamation,19 haematopoiesis,23 sens‐
ing oxidative stress,20 regulating macrophage responses in a tumor 
microenvironment,24	 and	 microglial	 colonization	 from	 periphery	
into	 developing	 brain	 (in	 zebrafish25).	 However,	 understanding	 of	
GPR132 function has been hampered because multiple other ligands 
have been published to activate GPR132, and selective pharmaco‐
logical tools for functional studies have not been available.
To address this, we adopted a chemical biology approach. First 
we identified synthetic drug‐like agonists to permit validation of cel‐
lular expression systems for GPR132. To screen a set of bioactive lip‐
ids, we employed yeast‐based assays to monitor GPR132 in isolation 
from other potentially confounding GPCRs, revealing N‐acylglycines 
as agonists. Small‐molecule antagonists of GPR132 block activation 
by N‐acylglycine. Rat and mouse GPR132 orthologs also act as recep‐
tors for N‐acylglycines	and	oxidized	fatty‐acids.	Structural	modelling	
suggests that binding of N‐acylglycines to GPR132 is analogous to 
lipid binding to other GPCRs, with lipid entry through the transmem‐
brane region. During our studies, Cohen et al described two further 
N‐acyl amino acids derived from the gut microbiota which also acti‐
vate GPR132.6,7	Our	data,	together	with	that	of	Cohen	et	al,	support	
a GPR132 signalling axis in the immune system with dual N‐acylgly‐
cine	and	oxidized	fatty‐acid	ligands,	which	may	play	distinct	roles	in	
different tissues and physiological contexts.
2  | METHODS
2.1 | Chemicals
N‐acyl amino acids and linoleamide were obtained from Cayman 
Chemical	(Ann	Arbor,	MI,	USA).	SKF‐95667,	SB‐583355,	SB‐583831,	
GSK1820795A, and telmisartan were prepared synthetically.
2.2 | Mammalian cell culture
Cell	lines	were	maintained	at	37°C	in	5%	CO2. DiscoverX PathHunter 
(CHO)	 cells	 were	 maintained	 using	 10%	 heat‐inactivated	 fetal	
bovine	 serum	 (HI‐FBS)	 in	 Dulbecco's	 minimal	 essential	 media	
(DMEM):Ham's	F‐12	(1:1)	with	2	mmol/L	L‐glutamine.	Selection	was	
maintained using G418 (800 μg/mL)	and	hydromycin‐B	(300	μg/mL).	
Rat	basophilic	 leukemia	(RBL)	cells	were	maintained	in	DMEM	F12	
supplemented	with	10%	HI‐FBS	at	37°C	and	5%	CO2. RBL cells sta‐
bly	expressing	human	GPR132a	(RBL‐GPR132)	were	supplemented	
with	G418	(500	µg/mL).
GeneBLAzer™	 T‐REx™‐G2A(GPR132)‐NFAT‐bla	 FreeStyle™	
293F	cells	were	maintained	according	to	manufacturer's	instructions	
(ThermoFisher	Scientific).
2.3 | Ca2+ microfluorimetry
A	 digital	 epifluorescence	 imaging	 system	 (Perkin‐Elmer)	 incorporat‐
ing	an	Olympus	BX50WI	microscope	was	used	 to	measure	 changes	
in intracellular Ca2+ levels in individual cells. Cells grown overnight to 
~80%	confluency	on	poly‐D‐lysine‐treated	glass	coverslips	 (0.9	mm)	
were serum starved in 0.2% FBS. Cells were incubated for 50 minutes 
with the Ca2+ sensitive dye Fura 2‐AM (6 μmol/L)	in	HEPES	buffered	
saline (HBS: NaCl 135 mmol/L, HEPES 10 mmol/L, KCl 5 mmol/L, 
CaCl2 1.8 mmol/L, MgCl2	1	mmol/L,	D‐glucose	25	mmol/L,	pH	7.4).	
For experimentation, cells were perfused with HBS at a rate of ~2 mL/
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min	 (28‐30°C)	 and	 ratiometric	 images	 (350/380	 nm)	were	 collected	
at	 5	 second	 intervals	 using	 MetaFluor	 software	 (Universal	 Imaging	
Corporation).	Data	 from	multiple	 individual	 cells	within	 a	 field	were	
collated from three independent experiments for analysis.
2.4 | β‐arrestin association assay
hGPR132a and mGPR132 were separately cloned into DiscoverX 
Prolink vectors and transfected into HEK293 cells which stably 
express β‐arrestin2‐β‐gal‐EA fusion protein. Cells were plated in 
384‐well white‐opaque bottom (12 000 cells/well in 20 μL)	in	F‐12	
medium containing 10% FBS. After 4 hours, media was removed 
and cells were serum starved in 0.2% FBS overnight. Test ligand 
diluted in F12 media (2 μL	per	well;	90	minutes,	37°C)	followed	by	
DiscoverX reagent solution (12 μL	per	well;	30	minutes,	37°C)	were	
added and plates read using an Envision luminescence plate reader.
2.5 | NFAT reporter gene assay
To identify GSK1820795A, 2256 compounds were dispensed into black 
clear‐bottom	 384‐well	 plates	 (Greiner)	 as	 solutions	 in	 100%	DMSO	
(40	 nL/well;	 final	 concentration	 1	 µmol/L),	 using	 an	 Echo	 accoustic	
dispenser	 (Labcyte).	 GeneBLAzer™	 T‐REx™‐G2A(GPR132)‐NFAT‐bla 
FreeStyle™	293F	cells	were	thawed,	resuspended	in	90%	DMEM;	10%	
dialyzed	FBS;	0.1	mmol/L	NEAA;	25	mmol/L	HEPES	(pH	7.3);	100	U/mL	
Penicilin; 100 µg/mL Streptomycin, and added to wells (10 000 cells/
well	in	40	µL).	Media	was	supplemented	with	1	ng/mL	doxycycline	to	
induce expression of GPR132, resulting in high GPR132 constitutive 
activity.	 After	 incubtion	 (18	 hours	 at	 37°C;	 5%	CO2),	 LiveBLAzer™‐
FRET β‐galactosidase	substrate	(CCF‐AM)	prepared	according	to	man‐
ufacturer’s	instructions	(ThermoFisher	Scientific,	Loughborough,	UK)	
was	added	(8	µL/well;	room	temperature	for	2	hours).	Inverse	agonists	
including GSK1820795A were identified from the 460/530 nm emis‐
sion	ratio	(Envision,	Perkin	Elmer)	by	reference	to	doxycycline‐treated	
and	untreated	controls.	Half‐maximal	inhibition	(pIC50)	values	were	de‐
termined in similar experiments, except that cells were supplemented 
with	SKF‐95667	(1	µmol/L).
2.6 | Angiotensin AT1 antagonist assay
Chinese	Hamster	Overy	 (CHO)	cells	stably	expressing	human	angio‐
tensin AT1 and containing luciferase under an NFAT‐responsive pro‐
moter (NFAT‐hAT1‐CHO)	were	used.	Briefly,	cells	are	 incubated	with	
30	nmol/L	angiotensin	 II	 for	18	hours,	 in	 the	presence	of	 test	 com‐
pound.	Luciferase	activity	was	quantified	using	Bright‐Glo™	Luciferase	
reagent	(Promega),	measured	on	the	Lumistar	Galaxy	(BMG	Labtech).
2.7 | Activation of the yeast pheromone‐
response pathway
Modified yeast used to express mammalian GPCRs and measure 
GPCR activation have been described previously.26 GPR132 or‐
thologs were cloned into pRS306GPD for chromosomal integration. 
Human	GPR132a	 (hGPR132a)	was	 integrated	 into	MMY24	 (Gpa1/
Gαi3)	 to	 generate	 YIG95.	 GPR132b	 (hGPR132b)	 isoform	 and	 rat	
GPR132	 (rGPR132)	 were	 also	 integrated	 into	 MMY24.	 Mouse	
GPR132	(mGPR132)	was	integrated	into	MMY23	(Gpa1/Gαi1).	To	test	
for ligand specificity, yeast with chromosomally integrated human 
CB2	 (in	MMY23)	and	human	adenosine	A2A	 (in	MMY23)	 receptors	
were used. Mutant hGPR132‐pRS306GPD plasmids were generated 
by	DC	Biosciences	(Dundee,	UK)	and	integrated	into	MMY24.	Yeast	
expressing	GPR68	(OGR1)	were	generated	using	p426GPD	vector27 
transfected into MMY14 (Gpa1/Gαq5).	To	measure	agonist	activity,	
GPCR‐expressing	 yeast	 were	 plated	 at	 0.02	OD600nm/mL in black 
384‐well microtiter plates in the presence of test compound for 
24 hours at 30°C. Fluorescein production from FDGlu was quanti‐
fied using an Envision plate reader.
2.8 | Statistical analysis
Half‐maximal activities (pEC50	and	pIC50)	were	calculated	by	subject‐
ing technical replicates within an experiment to 4‐parameter logistic 
fitting,	 using	PRISM.	Values	 for	pEC50	 and	pIC50 are presented as 
mean ± standard deviation across separate experiments (n = experi‐
ment	days).	For	calcium	assay,	data	are	presented	as	mean	±	SE	of	
ratiometric fluorescent units. Two‐tailed unpaired Welch t‐test was 
used to compare the response of 10 μmol/L ligand in parental RBL 
cells	vs	hGPR132a‐RBL	cells.	Data	are	presented	as	non‐normalized	
fluorescence	counts,	or	normalized	to	the	maximum	response	of	a	
reference	full	agonist	(NPGly	or	NLGly	for	yeast	assays;	9‐HODE	or	
SB‐583831 for β‐arrestin	association	assays).
3  | RESULTS
At the outset of this project, we had access to the GPR132 agonist, 
SKF‐95667	(Figure	1A).	SKF‐95667	originates	from	a	collaboration	
between SmithKline Beecham and CADUS.28	 In	this	collaboration,	
synthetic surrogate agonists were identified at orphan GPCRs, by 
subjecting putative GPCRs to compound screening using the CADUS 
modified yeast (Saccharomyces cerevisiae)	as	expression	host.	Here	
we confirmed that SKF‐95667 activates the mating‐pheromone re‐
sponse pathway of yeast expressing human splice variant GPR132a 
(hGPR132a).	 Yeast	 strains	 used	 in	 this	 study	 are	 similar	 to	 those	
originally developed by CADUS, but include a chimeric Gα subunit 
to	optimize	communication	between	mammalian	GPCR	and	down‐
stream yeast signalling proteins.29	YIG95	yeast,	which	constitutively	
express hGPR132a and the Gpa1‐Gαi3 chimera, when treated with 
SKF‐95667	showed	a	 specific	 gene‐reporter	 response	 (Figure	S1).	
Half‐maximal (pEC50)	 concentrations	 and	maximal	 responses	 rela‐
tive to a reference agonist (%Emax)	 for	SKF‐95667	and	other	com‐
pounds tested in this study are shown in Table 1.
Obinata	 et	 al	 showed	 that	 10	 μmol/L	 9‐HODE	 induced	 Ca2+ 
transients	 in	 CHO	 cells	 overexpressing	 hGPR132a.13 Using yeast 
YIG95,	we	confirmed	9‐HODE	as	an	agonist	of	hGPR132a,	causing	a	
concentration‐dependent response (pEC50	=	5.9	±	0.14;	Figure	2A).	
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To further corroborate the ligand pairing, we used two mammalian 
hosts. Perfusion of rat basophilic leukemia cells expressing hG‐
PR132a	(RBL‐hGPR132a)	with	10	μmol/L	9‐HODE	induced	intracel‐
lular Ca2+	release	(Figure	3A).	No	response	was	detected	in	parental	
RBL	 cells	 (Figure	 3C).	We	 also	 used	 Chinese	 hamster	 ovary	 cells	
expressing	 a	 C‐terminally‐tagged	 version	 of	 hGPR132a	 (CHO‐hG‐
PR132aPL),	 in	 the	 PathHunter	 assay.	 9‐HODE	 induced	 association	
between hGPR132aPL and β‐arrestin (Figure 4A; pEC50	=	5.4	±	0.16),	
similar to results reported by others.15 Together, these data confirm 
9‐HODE	as	an	agonist	of	hGPR132a.
RBL‐hGPR132a cells were used to screen 6465 chemically di‐
verse compounds, measuring intracellular Ca2+	mobilization	using	the	
fluorescence	 imaging	plate	 reader	 (FLIPR).	Among	active	 agonists,	
SB‐583831 was chosen based on its potency and similarity to previ‐
ously described agonists.30	SB‐583831	activated	YIG95	(Figure	2B;	
pEC50	=	7.7	±	0.32)	whereas	yeast	expressing	either	GPR68	or	CB2 
were not activated up to 100 μmol/L	 (Figure	S1).	 SB‐583831	also	
induced association between hGPR132aPL and β‐arrestin (Figure 4B; 
pEC50	 =	7.3	±	0.17).	 SB‐583831	contains	 a	 glycine	 core	 linked	via	
amide	bonds	to	aliphatic	or	aromatic	appendage	groups	(Figure	1B),	
resembling hGPR132a agonists described previously.30 Compound 
1	 disclosed	 by	 Shehata	 et	 al	 (Figure	 1B)	 contains	 hydroxyacetate	
(glycolate)	 isosteric	 to	 glycine	 in	 SB‐583831.	 SB‐583831	 is	 >1	 log	
unit more potent than compound 1 (pEC50 = 7.3 compared to 5.5 for 
compound 1,30 in β‐arrestin	association	assays).	Appendage	groups	
of SB‐583831 and compound 1 also differ, so it is not clear whether 
glycine‐ or glycolate‐containing structures are preferred for GPR132 
binding.	 To	 identify	 antagonists,	 CHO‐hGPR132aPL cells were in‐
cubated with test compound prior to challenge with SKF‐95667. 
SB‐583355 inhibited agonist‐induced hGPR132aPL association with 
β‐arrestin, showing preliminary evidence of a concentration‐depen‐
dent	effect	(pIC50	≈	7.0;	n	=	2;	data	not	shown).	To	confirm	that	this	
F I G U R E  1   Structures of GPR132 
ligands described in this study
(A) Surrogate Agonist
Consensus structure
R1 & R3 = bulky aliphatic/aromatic
R2 = H or methylbenzyl
X = NH or O
GSK1820795A
(antagonist)
SKF-95667
(agonist)
Telmisartan
SB-583831
(agonist)
SB-583355
(antagonist)
(C) Telmisartan and analogues
Compound 1 (agonist)
Ref. [31]
(B) Glycine/glycolates and analogues
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effect was receptor‐specific, we showed that SB‐583355 inhibited 
SKF‐95667‐induced	activation	of	YIG95	(pIC50 = 6.5 ± 0.23; n = 5; 
data	not	 shown).	 SB‐583355	 is	 similar	 to	SB‐583831	but	 contains	
L‐phenylalanine	in	place	of	glycine	(Figure	1B).	Thus,	GPR132	ligands	
with either agonist or antagonist activity occur in the same struc‐
tural	series.	Exemplars	contain	amino	acid	(or	isostere)	linked	to	ar‐
omatic or aliphatic groups by amide or ester (consensus structure 
shown	in	Figure	1B).
Lipid GPCRs often have multiple endogenous cognate ligands. 
Cannabinoid receptor CB1, for example, is activated by lipids with 
ethanolamide and glycerol ester head groups (AEA and 2‐arachid‐
onylglycerol, respectively2).	 To	 identify	 candidate	 physiologically	
relevant	ligands	of	GPR132	beyond	9‐HODE,	we	screened	a	set	of	
lipids,	 using	 YIG95	 yeast	 to	 quantify	 agonist	 activity.	N‐linoleoyl‐
glycine	 (NLGly)	 and	 linoleamide	 were	 identified	 as	 novel	 GPR132	
agonists	 (Figure	2C	and	D).	9‐HODE	was	also	a	component	of	this	
lipid set and was identified alongside NLGly in the screen. Testing of 
further commercially available N‐acylglycines revealed N‐palmitoyl‐
glycine (NPGly; C16	side‐chain)	to	be	the	most	potent	N‐acylamide 
agonist of hGPR132a, among those tested (pEC50 = 6.2 ± 0.16, 
Figure	 2C).	 In	 the	 yeast	 assay,	 9‐HODE,	 SB‐583831,	 NPGly	 and	
CP‐55,940	 (see	 below)	 all	 behaved	 as	 full	 agonists	 of	 hGPR132a	
(Figure	2A‐E).	N‐hexanoylglycine (NHGly; C6	 side‐chain)	was	 inac‐
tive	(Table	1),	 indicating	a	minimum	side‐chain	 length	amongst	un‐
saturated N‐acylglycines between C6 and C16, for agonist activity. 
Linoleic acid had no detectable agonist activity up to 100 µmol/L 
(Figure	2D).	We	also	tested	lysophosphatidylcholine	(LPC),	since	this	
proinflammatory lipid was originally described to activate GPR132. 
We could detect no agonist or antagonist activity of LPC in any of the 
test	systems	used	(Table	1),	consistent	with	published	findings.13,15 
Lipid order‐of‐potency (based on yeast pEC50 values for hGPR132a 
activation)	was	NPGly	>	9‐HODE	≈	NLGly	≈	linoleamide	>	N‐oleoyl‐
glycine	 (NOGly)	 ≈	N‐stereoylglycine	 (NSGly)	 >	N‐arachidonoylgly‐
cine	(NAGly)	>	N‐docosahexanoylglycine	(NDGly)	(Figure	2A‐E).
We tested the effect of replacing glycine with other head 
groups. N‐oleoylserine	(NOSer)	activated	hGPR132a	more	potently	
than	NOGly	(Figure	2E;	pEC50 = 5.8 ± 0.07 and 5.1 ± 0.24, respec‐
tively).	However,	NOSer	 exhibited	 partial	 agonism	 (Emax = 21±5%; 
Figure	 2E)	 compared	 with	 the	 reference	 agonist	 SB‐583831,	 in	
contrast to N‐acylglycine agonists which typically had Emax	≥	80%	
(Table	 1).	 N‐arachidonyltyrosine	 (NATyr)	 was	 inactive,	 suggesting	
a steric limit on the N‐acylamide head group for GPR132 binding 
TA B L E  1   Structure‐activity relationship of N‐acylamides	at	GPR132.	Values	are	shown	as	mean	±	SD
Ligand
Receptor
Human GPR132a Rat GPR132 Mouse GPR132
Yeast β‐arrestin Yeast β‐arrestin
pEC50 (n) Emax pEC50 (n) Emax pEC50 (n) Emax pEC50 (n) Emax
NPGly 6.2	±	0.16	(7) 100 <5	(3) 14 7.0	±	0.12	(4) 53 ± 14 <5	(2) 11
9‐HODE 5.9	±	0.14	(4) 91 ± 8 5.5	±	0.13	(4) 100 6.2	±	0.12	(5) 100 5.6	±	0.23	(5) 97 ± 6
NLGly 5.8	±	0.08	(3) 84 ± 6 5.5	±	0.23	(2) 38 ± 4 6.5	±	0.36	(4) 68 ± 7 5.3	(1) 40
Linoleamide 5.8	±	0.01	(3) 79 ± 11 5.5	(1) 22 5.9	±	0.21	(2) 37 ± 5 <5	(1) IA
NOGly 5.1	±	0.24	(3) 95 ± 6 5.6	±	0.18	(2) 29 ± 15 NT NT 5.3	±	0.05	(2) 44 ± 10
NSGly 5.1	±	0.08	(3) 80 ± 4 5.4	(1) 23 NT NT <5	(1) IA
NAGly <4.5	(3) 38 IA	(2) IA 5.3	±	0.09	(4) 87 ± 12 NT NT
NHGly <5	(4) IA NT NT NT NT NT NT
NDGly <4.4	(4) 33 <5	(2) IA NT NT IA	(1) IA
NOSer 5.8	±	0.07	(4) 21 ± 5 NT NT NT NT NT NT
NATyr <4	(3) IA NT NT <4	(3) IA NT NT
2‐AG <5	(4) IA NT NT IA	(4) IA NT NT
Linoleic acid <4	(3) IA <5	(1) IA NT NT IA	(1) IA
LPC <4	(3) IA IA	(3) IA NT NT IA	(2) IA
SKF‐95667 6.6	±	0.26	(4) 99 ± 3 5.8	±	0.32	(2) 281 ± 81 IA	(3) IA 5.8	(1) 320
SB‐583831 7.7	±	0.32	(4) 95 ± 3 7.3	±	0.17	(5) 100 IA	(4) IA 7.5	±	0.3	(2) 100
CP‐55,940 5.5	±	0.13	(3) 102 ± 3 NT NT <5.5	(3) IA NT NT
Note: Number	of	independent	experiment	occasions	is	shown	in	parentheses	(n).	Typically	four	technical	replcates	were	conducted	on	each	experi‐
ment	occasion.	Values	based	on	limited	data	(n	≤	2)	require	further	experimentation	to	confirm.	For	yeast	assays,	raw	data	was	normalized	to	the	
effect	of	NPGly	(hGPR132a)	or	9‐HODE	(rGPR132a).	For	β‐arrestin	assays,	raw	data	was	normalized	to	the	effect	of	SB‐583831.	NT	=	Not	Tested.	
For	inactive	(IA)	compounds,	top	concentration	tested	is	shown	(for	example,	pEC50 < 4 denotes a compound tested up to 100 µmol/L for which no 
conentration‐response	curve	could	be	fitted).	For	compounds	which	showed	evidence	of	activity	at	higher	test	concentrations,	but	where	no	pEC50 
could be fitted, Emax	(%)	is	included.	Note	SKF‐95667	behaved	as	a	superagonist	(>100%	Emax)	at	both	hGPR132a	and	mGPR132	in	β‐arrestin assays, 
and did not activate rGPR132.
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(Table	 1).	 2‐arachidonylglycerol	 (2‐AG)	was	 inactive	 on	 hGPR132a	
(Table	 1).	 Several	 N‐acylamides	 including	 9‐HODE,	 NLGly	 and	
linoleamide produced bell shaped responses in the hGPR132a yeast 
assay	(Figure	2).	In	these	cases,	data	at	higher	concentrations	where	
response was depressed were excluded from curve fitting. The assay 
is based on yeast growth, and this signal depression was attributed 
to toxicity because control receptors were also inhibited in the same 
concentration	 range	 (Figure	 S1).	 Yeast	 expressing	 splice	 variant	 
hGPR132b31 were activated by N‐acylglycines with similar pharma‐
cology	to	hGPR132a	(Figure	S2).
F I G U R E  2   Agonist activation of yeast cells expressing human or rat GPR132. Yeast cells containing a gene‐reporter linked to the 
pheromone	response	pathway	and	engineered	to	express	human	GPR132a	were	treated	as	follows:	Oxidized	fatty	acid	9‐HODE13	(A);	
the	glycine‐containing	ligand,	SB‐583831	(C);	N‐palmitoylglycine	(NPGly;	C);	N‐linoleoylglycine	(NLGly;	C);	N‐stereoylglycine	(NSGly;	C);	
N‐arachidonoylglycine	(NAGly;	C);	N‐oleoylglycine	(NOGly;	D);	linoleamide	(D);	linoleic	acid	(D):	N‐oleoylserine	(NOSer;	E)	and	CP‐55,940	
(E).	Similarly,	yeast	expressing	rat	GPR132	were	treated	with	9‐HODE	(F);	N‐palmitoylglycine	(NPGly;	F);	N‐arachidonoylglycine (NAGly; 
F);	SB‐583831	(F);	N‐linoleoylglycine	(NLGly;	G);	linoleamide	(G)	and	CP‐55,940	(G).	Ligand	responses	were	normalized	to	the	effect	of	
NPGly	(for	hGPR132a)	or	9‐HODE	(for	rGPR132).	Data	are	presented	as	mean	±	SEM	(from	n	=	3	to	7	independent	experiments	per	ligand;	
four	technical	replicates	were	conducted	for	each	condition).	N‐acylamide ligands caused inhibition of yeast cell growth at concentrations 
>10 µmol/L or >30 µmol/L, and these were therefore used as the top threshold test concentrations curve‐fitting
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To examine specificity of N‐acylamides for GPR132, we tested 
three other family‐A GPCRs expressed in yeast. GPR68 sequence 
is	related	to	GPR132,	but	GPR68	responds	to	acid	pH	(protons)	and	
no endogenous lipids are known to activate GPR68.32 CB2 binds 
N‐acylamide	ligands	(AEA	and	2‐arachidonylglycerol)	but	has	low	se‐
quence similarity to GPR132. Adenosine A2a has neither sequence 
similarity nor comparable ligands to GPR132.33	 In	 general,	 the	N‐
acylamides were inactive at GPR68, CB2 and A2a, indicating they 
are	 specific	 agonists	of	GPR132	 (Figure	S1).	Unexpectedly,	NAGly	
showed weak partial agonist activity on CB2 (pEC50 = 5.6 ± 0.3, 
Emax	 =	 17±2%,	 n	 =	 3;	 Figure	 S1).	NAGly	 does	 not	 bind	CB2 when 
tested up to 10 µmol/L,34 but our data raise the possibility of an 
interaction between NAGly and CB2 in higher concentration ranges. 
Unexpectedly CP‐55,940 also activated hGPR132a (Figure 2E; 
pEC50 = 5.5 ± 0.13, Emax	=	102	±	3%),	though	more	weakly	than	CB2 
(Figure S1; pEC50 = 7.6 ± 0.27, Emax	=	100%).	CP‐55,940	is	a	synthetic	
analogue of the Cannabis sativa constituent, Δ9‐tetrahydrocannabi‐
nol. CP‐55 940 also modulates the lysophophaditylinositol receptor, 
GPR55.35,36 GPR132 is the fourth lipid receptor (in addition to CB1, 
CB2,	and	GPR55)	modulated	by	CP‐55	940.
To confirm the ligand pairing, we perfused RBL‐hGPR132a 
cells with 10 μmol/L NLGly, which induced intracellular Ca2+ re‐
lease	comparable	 to	9‐HODE	 (Figure	3B&C).	NLGly	 induced	asso‐
ciation of hGPR132 with β‐arrestin (Figure 4C; pEC50 = 5.5 ± 0.2, 
Emax	=	39±4%).	NOGly	had	similar	activity	to	NLGly	whereas	NPGly	
and	NSGly	were	 less	 active	 (Figure	4C).	N‐acylglycines act as less 
efficacious or less potent agonists to induce hGPR132a association 
with β‐arrestin,	compared	with	9‐HODE,	which	acts	as	a	full	agonist.	
This is in contrast to G‐protein‐mediated signals (in RBL‐hGPR132a 
and	yeast)	where	N‐acylglycines	and	9‐HODE	are	equi‐efficacious	
(Figures	2	and	3).	9‐HODE	and	N‐acylglycines are thus potentially 
able to elicit differential cellular responses via the same receptor. 
During our studies, Cohen et al showed two structurally‐related 
N‐acyl	amino	acids	to	stimulate	association	of	hGPR132	(G2A)	with	
β‐arrestin. N‐acyl‐3‐hydroxypalmitoylglycine	(commendamide)7 and 
N‐myristoylalanine6 are products of N‐acyl	amide	synthase	enzymes	
F I G U R E  3  9‐HODE	and	NLGly	induce	calcium	transients	in	
Rat	Basophilic	Leukemia	(RBL)	cells	overexpressing	hGPR132a.	
Representative transient calcium release measurements taken from 
microfluorimetry	experiments	showing	effect	of	(A)	9‐HODE	and	
(B)	NLGly	(both	10	µmol/L)	on	RBL‐hGPR132a	cells.	Each	trace	
represents	an	individual	cell.	(C)	NLGly	(10	µmol/L)	induced	Ca2+ 
transients in RBL‐hGPR132a cells (0.138 ± 0.03 ratio units, n = 17 
cells),	significantly	greater	than	observed	in	parental	RBL	cells	
(0.040 ± 0.008 ratio units, n = 14 cells, t	(17.78)	=	2.88,	P	=	.01).	
Similarly,	9‐HODE	(10	µmol/L)	induced	Ca2+ in RBL‐hGPR132a cells 
(mean,	peak	response:	0.122	±	0.016	ratio	units,	n	=	46	cells),	with	
little or no response detected in parental RBL cells (0.023 ± 0.003 
ratio units, n = 27 cells; t	(48.39)	=	6.27;	P	=	<.0001).	*P < .05 
**P < .01
F I G U R E  4   N‐acylglycines induce 
association of human and mouse 
GPR132 with β‐arrestin.	CHO	cells	
stably expressing C‐terminally tagged 
human	(A‐C)	or	mouse	GPR132	(D‐F)	
(CHO‐hGPR132aPL	or	CHO‐mGPR132PL)	
were challenged with agonists as follows: 
9‐HODE	(A	and	D);	SB‐583831	(B	and	
E);	linoleic	acid	(C)	and	N‐acylglycines 
(C	and	F).	N‐acylglycines tested were N‐
linoleoylglycine	(NLGly),	N‐oleoylglycine 
(NOGly),	N‐palmitoylglycine	(NPGly),	and	
N‐stereoylglycine	(NSGly).	PathHunter	
assay was used to measure receptor‐β‐
arrestin	interaction.	Data	were	normalized	
to the maximal effect of SB‐583831 
(100%)	in	each	experiment,	and	are	
presented as mean ± SEM (from n = 2 
to 7 independent tests per ligand with 2 
technical	replicates	per	experiment)
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of gut‐resident bacteria proposed to modulate host immune 
responses	in	via	GPR132.	Our	data,	together	with	that	of	Cohen	et	al, 
confirm N‐acyl amino acids as bona fide activators of hGPR132.
Family A GPCRs have varying degrees of homology across mam‐
mals. Assuming most physiological processes change little through 
mammalian evolution, specificity for cognate ligands is expected to 
be conserved even where GPCR sequence conservation is not high, 
due to selective pressure to retain affinity and activity. hGPR132 
and	mouse	GPR132	 (mGPR132)	 are	 68%	 identical.	 Thus,	 GPR132	
appears less well‐conserved than CB2, CB1, or GPR68 (respectively 
83%,	97%,	and	92%	 identical	between	human	and	mouse).	No	ac‐
tivation	of	mGPR132	by	9‐HODE	was	originally	observed.14 Those 
authors concluded GPR132 may have distinct roles in human and 
rodent, and the late‐onset autoimmune syndrome in GPR132‐null 
mice37 may not be relevant to human. We developed yeast express‐
ing	rGPR132.	9‐HODE,	NPGly,	NAGly	(Figure	2F)	and	also	NLGly	and	
linoleamide	(Figure	2G)	activated	rGPR132,	with	potencies	compa‐
rable	to	those	observed	at	hGPR132	(Table	1).	We	fused	a	C‐terminal	
ProLink	 tag	 to	mGPR132.	 In	HEK293	 cells	 expressing	 EA‐β‐arres‐
tin,	9‐HODE	(Figure	4D),	SB‐583831	(Figure	4E),	NLGly	and	NOGly	
(Figure	4F)	induced	association	between	mGPR132PL and β‐arrestin. 
Ligands	 inactive	 at	 hGPR132	 (NHGly,	 linoleic	 acid,	 and	 LPC)	were	
inactive	at	mGPR132	and	rGPR132	(Table	1).	In	conclusion,	the	phar‐
macological profile of N‐acylglycines	and	oxidized	free	fatty	acids	is	
conserved across mammalian GPR132 orthologs.
N‐acylglycines and SB‐583831 share a glycine moiety 
(Figure	 1B).	 To	 determine	 whether	 these	 internal	 glycines	 bind	
a common GPR132 site, we conducted antagonist Schild analy‐
sis. GSK1820795A had been identified as an hGPR132 antagonist 
(see	 Methods).	 GSK1820795A	 is	 an	 analogue	 of	 telmisartan,	 the	
dual angiotensin AT1 antagonist and PPARγ	modulator	 (Figure	1C).	
AT1 antagonism by GSK1820795A and telmisartan are compa‐
rable	 (not	shown;	pIC50	=	8.2	±	0.13;	n	=	3	and	pIC50 = 8.6 ± 0.3; 
n	=	28,	respectively).	GSK1820795A	blocks	agonist‐induced	activa‐
tion	of	hGPR132	 (Figure	5A‐D).	GSK1820795A	did	not	antagonize	
free fatty acid receptor FFA2	(Figure	5E),	confirming	specificity	for	
GPR132. GSK1820795A blocked agonist‐induced association of 
hGPR132 with β‐arrestin	(not	shown;	pIC50	=	7.8	±	0.22;	n	=	13),	and	
we have preliminary evidence that GSK1820795A blocks rGPR132 
(n	=	2;	 not	 shown).	Maximum	asymptotes	 (Emax)	 for	NPGly,	NLGly	
and	linoleamide	(Figure	5A‐C)	were	reduced	by	increasing	concen‐
trations of GSK1820795A with minimal change to pEC50, typical of 
non‐competitve antagonism. GSK1820795A caused rightward shifts 
of SB‐583831 agonist‐response curves with minimal change to Emax 
(Figure	5D),	 in	contrast	to	N‐acylamides. Schild regression showed 
linearity	 (Figure	 S3B).	 GSK1820795A	 was	 ≈10‐fold	 more	 potent	
than	telmisartan	as	an	antagonist	of	hGPR132	(Figure	S3).	It	was	un‐
clear whether GSK1820795A acted as a competitive antagonist of 
SB‐583831, since Hill slope differed from unity (nH = 1.9 for both 
GSK1820795A	and	 telmisartan;	Figure	S3B).	Extending	antagonist	
F I G U R E  5   GSK1820795A is a selective antagonist at hGPR132a. Telmisartan analogue GSK1820795A was identified as a GPR132 
antagonist	through	high‐throughput	screening.	Responses	of	yeast	expressing	hGPR132a	to	agonists	NPGly	(A),	NLGly	(B),	linoleamide	(C),	
and	SB‐583831	(D)	were	blocked	by	GSK1820795A	in	a	concentration‐dependent	manner.	Maximal	effects	NPGly,	NLGly,	and	linoleamide	
(A‐C)	were	depressed	by	GSK1820795A	with	little	effect	on	EC50.	In	contrast,	GSK1820795A	caused	rightward	shifts	of	concentration‐
response curves to SB‐583831 without reducing maximal responses. The effect of telmisartan on hGPR132a and Schild analysis are 
presented in Figure S3. Agonist responses of yeast expressing GPR43/FFA3 to propionate were not significantly affected by GSK1820795A 
(E).	Data	points	show	mean	±	SD	of	four	technical	replicates	(non‐normalized	fluorescent	counts)	from	a	representative	experiment
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preincubation time from 5 to 45 minutes had no effect on Hill slope 
(not	 shown),	 suggesting	 non‐unity	Hill	 slopes	were	 not	 caused	 by	
insufficient binding equilibration. We concluded that N‐acylglycines 
and SB‐583831 have distinct modes of binding to GPR132.
To probe further the interaction of GPR132 with lipids, we 
predicted a 3D pose for N‐acylglycine	 and	 9‐HODE	 binding,	 and	
tested this by mutagenesis. A 3D homology model of hGPR132 
from GPCRdb was used.38 Due to the flexible acyl side‐chain of 
both ligands, we adopted an “anchor and grow” approach (see 
Figure	S6).	9‐HODE	is	similar	to	ligands	of	FFA1. Carboxylate‐bind‐
ing residues in FFA1 have been established by mutagenesis
39 and 
crystallization.40,41	We	 hypothesized	 that	 lipid	 heads	 groups	 bind	
GPR132 in an equivalent pocket, so we focused on this region as 
the initial anchoring site (residues 4.57, 5.39, 5.42, 6.51, and 6.55 
by	Ballesteros‐Weinstein	numbering).	Meta‐analysis	of	the	ternary	
complex between FFA1, fatty‐acid mimetic MK‐8666 and allosteric 
ligand AP8 further supported importance of these residues (Figure 
S4).	“Anchor	and	grow”	docking	yielded	superimposable	and	repro‐
ducible	 low‐energy‐scoring	binding	poses	for	9‐HODE	and	NPGly.	
Growth trees with the best grid scores are shown in Figures S6 
and	 S7.	 The	 lowest‐energy	 binding	 poses	 for	 9‐HODE	 and	NPGly	
are	highly	similar	(Figure	6).	At	neutral	pH,	negatively	charged	lipid	
headgroups	 are	 predicted	 to	 stabilize	 a	 charge	 network	 involving	
Y200	(5.39),	Y258	(6.51),	K265	(6.58),	and	K183	(ECL2).	We	noted	a	
potential	interaction	between	R203	(5.42)	and	the	alkyl	side	chain	of	
both	9‐HODE	and	NPGly.	This	residue	is	conserved	across	GPR132	
orthologs.	 In	 published	GPCR	 structures,	 residue	 5.42	 often	 lines	
the “classical” ligand‐binding pocket. Residue 5.42 tends to contrib‐
ute	more	to	agonist	than	antagonist	binding	(Figure	S5).	We	mutated	
R203	 (5.42)	 and	adjacent	 residues	Y199	 (5.38)	 and	Y200	 (5.39)	of	
hGPR132a, and also K183 in ECL2. Agonist potencies for a panel 
of	ligands	is	shown	in	Figure	7	and	Table	S1.	Mutant	R203A	(5.42)	
abolished	responses	to	NPGly	and	NLGly	(Figure	7C	and	D).	These	
effects were unlikely to be due to reduced expression of hGPR132a, 
since R203A responded to CP‐55,940 with a potentiated response 
(wild‐type: pEC50 = 5.64 ± 0.08; R203A: pEC50 = 7.04 ± 0.06; 
Figure	 7B	 and	 Table	 S1).	 These	 observations	 are	 consistent	 with	
our	 binding	 pose,	 and	 the	 hypothesis	 that	 R203(5.42)	 contributes	
significant energy to N‐acylglycine binding. Strikingly, SB‐583831 
had no agonist activity but appeared to act as an inverse agonist 
on	R203A,	 inhibiting	basal	 signaling	 (Figure	7A;	pIC50 = 7.7 ± 0.2; 
n	=	3).	Mutants	K183A	(ECL2)	and	Y199A	(5.38)	retained	agonist	re‐
sponses, suggesting neither residue contributes to ligand binding or 
G‐protein	activation.	Responses	of	K183A	(ECL2)	and	Y199A	(5.38)	
to N‐acylglycines were somewhat potentiated compared with wild‐
type	(Figure	7C	and	D),	which	could	be	due	to	increased	receptor	ex‐
pression.	Mutant	Y200A	(5.39)	responded	to	SB‐583831	with	similar	
pEC50 as wild‐type, showing that Y200A is expressed and retains the 
ability	 to	respond	to	agonists	 (Figure	7A).	N‐acylglycines activated 
Y200A but with substantially reduced Emax compared with wild‐type 
F I G U R E  6   Proposed binding poses of 
NPGly	and	9‐HODE	docked	to	GPR132	
homology model, showing suggested 
hydrophobic interactions of acyl side‐
chains perpendicular to the guanidinium 
plane	of	R203(5.42):	(A)	NPGly;	(B)	9‐
HODE;	(C)	overlay	of	9‐HODE	and	NPGly
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(Figure	7C	and	D).	Activation	by	CP‐55,940	was	abolished	in	Y200A	
(Figure	7B).	Residue	5.39	in	the	free‐fatty	acid	receptors	(FFA1‐3)	is	
arginine, forming the critical salt‐bridge to carboxylate‐containing 
agonists.39,41 The effect of Y200A on activation of hGPR132a by N‐
acylglycines supports the hypothesis that there are similarities in the 
mode of binding of lipid agonists between GPR132, FFA1‐3, and other 
lipid‐binding	Family‐A	GPCRs.	In	summary,	modelling	identified	resi‐
dues in GPR132 important in binding N‐acylglycines and other novel 
agonists examined in this study. Combined with the effects of an‐
tagonist	GSK1820795A	 (Figure	 5),	 our	 data	 differentiate	 between	
GPR132 agonists with flexible acyl side‐chains (N‐acylamides)	 and	
more rigid small‐molecule surrogate agonists such as SB‐583831.
4  | DISCUSSION
Here we show that endogenously‐occurring N‐acylamides activate 
the orphan receptor, GPR132. To gain confidence in this ligand 
pairing, we identified small‐molecule agonists and antagonists of 
GPR132, also disclosed here. This chemical biology approach, start‐
ing with the surrogate agonist, SKF‐95667, allowed validation of 
multiple host systems for functional GPR132 expression, before 
screens of endogenously‐occurring lipids were conducted. N‐acyla‐
mides trigger intracellular Ca2+ release in RBL‐hGPR132a cells, in‐
duce association between hGPR132a and β‐arrestin, and activate 
the G‐protein‐linked pheromone response pathway of yeast cells 
expressing hGPR132a. GSK1820795A blocks activation of yeast 
cells expressing hGPR132a by N‐acylamides. Activation of rat and 
mouse GPR132 by N‐acylamides further supports the ligand pairing. 
We	 corroborate	 9‐HODE	 as	 a	 candidate	 endogenous	 agonist	 for	
hGPR132.14,15	Our	data	are	consistent	with	activation	of	Gαi path‐
ways by GPR132.13 Chimeric Gpa1‐Gαi3 supported hGPR132 sig‐
nalling in yeast, and Gαi activation in RBL cells has been shown to 
trigger Ca2+	mobilization.42 We show for the first time that rGPR132 
and	mGPR132	are	also	activated	by	9‐HODE.	Broadly,	9‐HODE	and	
N‐acylglycines have comparable effects on GPR132, which is unsur‐
prising given their similar structures.
N‐acylserine	 (NOSer;	 Figure	 2)	 and	 N‐acylalanine6 also acti‐
vate GPR132, though N‐acylglycines appeared most efficacious. 
Moreover,	 a	 specific	 biosynthetic	 enzyme	 for	 N‐acylglycines, 
GLYATL2,	has	been	characterized	suggesting	biological	relevance.5 
Few N‐acyl derivatives of larger amino acids are commercially avail‐
able. N‐arachidonyltyrosine was inactive, but arachidonate is not 
an optimal side‐chain for GPR132 activation. A full understanding 
of SAR will require a systematic evaluation across N‐acyl amino 
acids with a common, optimal acyl groups for GPR132 activation. 
We observed no activation of GPR132 by free linoleic acid up to 
100 µmol/L in either yeast or β‐arrestin assocation assays, in agree‐
ment with,13 though not.15 Amidation of linoleic acid to linoleamide 
confers	agonist	activity	(Figure	2).	This	contrasts	with	FFA	receptors,	
where fatty acid amidation abolishes agonism.43 We also disclose 
SB‐583831 and SB‐583355 as peptidomimetic GPR132 agonist and 
antagonist. These are based on amino acid templates (glycine in 
SB‐583831;	L‐phenylalanine	in	SB‐583355)	with	structural	similarity	
to previously described agonists.30
Yeast	is	suited	to	GPCR	deorphanization	because	no	potentially	
confounding GPCRs are encoded in the yeast genome (the pher‐
omone	 receptor,	 Ste2p,	 is	 deleted).	 Inadvertent	 upregulation	 of	
F I G U R E  7   Yeast assay showing the 
effect of hGPR132a residue mutagenesis 
on	the	agonist	potency	of	ligands:	(A)	
SB‐583831,	(B)	CP‐55,940,	(C)	NPGly,	
(D)	NLGly.	hGPR132a	sequences	are	
represented	as	follows:	K183A	(purple),	
Y199A	(cyan),	Y200A	(blue),	R203A	
(green),	and	wild‐type	(black).	Response	
data	for	each	mutant	were	normalized	
to effects of the corresponding ligand 
at wild‐type hGPR132a. SB‐583831 did 
not activate mutant R203A but showed 
an inverse agonist concentration‐
response, inhibiting the elevated basal 
signal (elevated basal is due to receptor 
constitutive	activity).	Data	are	presented	
as mean ± SEM of n = 3 independent 
experiments
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endogenous mammalian GPCRs is a common pitfall of orphan GPCR 
studies,	and	may	explain	why	initial	deorphanizations	are	not	always	
reproduced.	 Other	 GPCRs	 reportedly	 activated	 by	N‐acylglycines 
(LPA5	and	GPR18)	could	not	be	responsible	for	effects	observed	at	
GPR132 in yeast. The pharmacological profile of GPR18 is contro‐
versial: multiple groups report NAGly activity,8‐10 other publications 
do not reproduce this.15,44 The recent identification of synthetic 
GPR18 ligands should allow resolution of authentic ligand speci‐
ficity, as has been the case for other controversial GPCRs.45,46 We 
observed evidence of weak activation of yeast expressing CB2 by 
NAGly. NAGly did not bind CB2 up to 10 µmol/L,
34 but the possibility 
of an interaction between CB2 and NAGly at higher concentration 
merits further investigation.
LPC and lactate have been published as GPR132 ligands, but 
have not gained widespread acceptance (one publication was 
retracted47).	GPR132	was	also	reported	as	a	sensor	of	extracellular	
pH,48 but other authors were unable to replicate these observa‐
tions.32,49 GPR4, GPR65, and GPR68, whose pH‐sensing activity is 
well‐established,	have	significant	similarity	to	each	other.	In	contrast,	
GPR132 is more distantly related, showing homology also to puri‐
nergic receptors,50 and three of the four basic amino acids involved 
in pH‐sensing by GPR4, GPR65, and GPR68 are non‐basic residues 
in GPR132.50	Discovery	 of	 9‐HODE	 allowed	direct	 comparison	of	
the	effect	of	acidic	pH	to	a	molecular	agonist.	9‐HODE	was	approxi‐
mately 10‐fold more efficacious than acidic pH.13 Considering these 
factors, and the challenges in discriminating specific effects of pH on 
receptors from the effects of pH on host cells, we present here data 
generated	 in	buffered	conditions	 (constant	pH),	 to	 show	pH‐inde‐
pendent agonist effects.
We postulated lipids to enter GPR132 via a crevice between TM4 
and TM5 domains and to occupy similar poses. Acyl groups extend 
through the TM4/TM5 crevice into the lipid bilayer, accommodat‐
ing larger acyl groups (C20 in 11‐HETE
13).	Acyl	chains	are	predicted	
to	 interact	with	R203	 (5.42)	via	hydrophobic	 interactions	perpen‐
dicular to planar guanidinium.51	R203A	 (5.42)	mutation	eliminated	
the	activity	of	NPGly,	NLGly	and	NOGly,	consistent	with	our	model.	
Phenotypes of mutations discriminated agonists into three classes, 
which may correspond to different binding modes to GPR132. 
R203A	 (5.42)	 eliminated	 activity	 of	 N‐acylglycines, whereas 
CP‐55,940 retained its agonist effect. This is consistent with crys‐
tal structures of AM11542 and AM841 in CB1, which showed that 
structurally equivalent 5.43 in CB1 is not essential for interaction 
with Δ9‐tetrahydrocannabinol derivatives.52	R203A	(5.42)	retained	
affinity for SB‐583831 but efficacy was lost and it behaved as an 
inverse agonist. Similar studies on β2 adrenoceptor showed the po‐
tential	 importance	of	S203	(5.42)	rotameric	conformation	in	medi‐
ating inverse versus full agonism of ligands.53	Mutant	Y200A	(5.39)	
had no effect on SB‐583831 but substantially reduced reponses 
to N‐acylglycines and abolished responses to CP55940. Previous 
studies have shown residue 5.39 to influence binding of CP‐55,940 
to CB1.
54 Together, our data raise the possibility of a comparable 
pocket on two lipid receptors, CB1 and hGPR132a, able to accom‐
modate CP‐55,940. A limitation of our functional assay data is that 
it does not distinguish mutational effects on efficacy and affinity. 
It	will	be	informative	to	analyze	mutations	using	probes	to	directly	
quantify affinity at GPR132, and reliable antibodies to measure pro‐
tein expression, when such tools become available. An alternative 
interpretation	is	that	R203	(5.42)	forms	a	salt‐bridge	to	carboxylate	
and	Y200	(5.39)	forms	a	carboxylate‐stabilizing	 interaction,	as	ob‐
served in the FFA1‐TAK‐875 structure.
41 Confidence in the structure 
of GPR132 and pose of bound ligands will require crystallography or 
other biophysical methods.
How does the identification of N‐acylglycines as ligands for 
GPR132	advance	understanding	of	 this	multi‐functional	GPCR?	 In	
general, N‐acylglycines are anti‐inflammatory 3,12 and anti‐nocicep‐
tive,12	whilst	9‐HODE	is	proinflammatory	20 and pro‐nociceptive.21 
These differences could relate to preferential activation of separate 
pathways downstream of GPR132. N‐acylglycines induced weaker 
association	 of	 ß‐arrestin	 with	 GPR132	 compared	 to	 9‐HODE,	
whereas NPGly activated GPR132‐expresssing yeast more strongly 
than	 9‐HODE.	 However,	 the	 situation	 is	 complicated	 because	 9‐
HODE	also	activates	PPARγ, a known modifier of macrophage ac‐
tivation.55,56 N‐acylglycines also are unlikely to be selective for 
GPR132.4	 Both	9‐HODE	 and	N‐acylamides	 (such	 as	AEA)	 interact	
with	TRPV1.57,58 We have not tested the panel of N‐acylglycines at 
TRPV1,	but	the	GPR132	antagonist	SB‐583355	is	inactive	at	TRPV1	
(tested	at	a	single	concentration;	12.5	µmol/L)	so	might	allow	confir‐
mation of GPR132‐mediated lipid effects in tissue. Structure‐activity 
relationship	(SAR)	for	N‐acyl amino acid stimulation of PGJ produc‐
tion by mouse RAW cells16 resembles, at least in part, order‐of‐po‐
tency at GPR132, with NLGly being more active than NAGly. Thus, 
RAW cell activation may be mediated by GPR132. However, selec‐
tive blockade will be required to conclusively attribute GPR132‐me‐
diated effects of N‐acylglycines	and	oxidized	fatty	acids	in	primary	
cells,	and	in	vivo.	Oxidized	fatty	acids	are	produced	in	skin	and	other	
tissues	under	stress	conditions,	such	as	exposure	to	UV	light.	Hattori	
et al found that skin keratinocytes under oxidative stress upregulate 
GPR132,	and	9‐HODE	treatment	causes	GPR132‐mediated	intracel‐
lular Ca2+ release in these cells.20 The identification of N‐acylglycines 
as GPR132 ligands also points to functions in barrier tissues, since 
skin fibroblasts express high levels of GLYATL2.5 N‐acylglycines 
from skin fibroblasts may signal to GPR132 on local keratinocytes, 
or	to	 infiltrating	or	tissue‐resident	macrophages.	At	sites	of	zymo‐
san‐induced inflammation, GPR132 functions to position infiltrating 
macrophages into proinflammatory microenvironments, facilitating 
M1‐like differentiation and production of proinflammatory media‐
tors.19 N‐acylglycines signalling to GPR132 in dermis may operate 
in a similar way.
In	conclusion,	GPR132	is	activated	by	two	lipid	classes:	oxidized	
fatty	acids	exemplified	by	9‐HODE	and	11‐HETE,	and	N‐acyl amino 
acids,	exemplified	by	NPGly	and	NLGly.	Oxidized	fatty	acids	are	as‐
sociated with pathological states such as oxidative stress. N‐acyl‐
glycines are produced by dedicated biosynthetic pathways under 
non‐pathological conditions. Knowledge of the endogenous ligands 
of GPR132 will be crucial to fully understand the immunomodula‐
tory roles of this GPCR.
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